{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:35:57Z","timestamp":1789050957194,"version":"build-2803163510"},"reference-count":112,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    Leukemia represents a diverse group of hematopoietic neoplasms that can be classified into different subtypes based on the molecular aberration in the affected cell population. Identification of these molecular classification is required to identify specific targeted therapeutic approaches for each leukemic subtype. In general, targeted therapy approaches achieve good responses in some leukemia subgroups, however, resistance against these targeted therapies is common. In this review, we summarize molecular drug resistance biomarkers in targeted therapies in BCR::ABL1-driven chronic myeloid leukemia (CML) and JAK2-driven myeloproliferative neoplasms (MPNs). While acquisition of secondary mutations in the BCR::ABL1 kinase domain is the a common mechanism associated with TKI resistance in CML, in JAK2-driven MPNs secondary mutations in JAK2 are rare. Due to high prevalence and lack of specific therapy approaches in MPNs compared to CML, identification of crucial pathways leading to inhibitor persistence in MPN model is utterly important. In this review, we focus on different alternative signaling pathways activated in both, BCR::ABL1-mediated CML and JAK2-mediated MPNs, by combining data from\n                    <jats:italic>in vitro<\/jats:italic>\n                    and in vivo-studies that could be used as potential biomarkers of drug resistance. In a nutshell, some common similarities, especially activation of PDGFR, Ras, PI3K\/Akt signaling pathways, have been demonstrated in both leukemias. In addition, induction of the nucleoprotein YBX1 was shown to be involved in TKI-resistant JAK2-mediated MPN, as well as TKI-resistant CML highlighting deubiquitinating enzymes as potential biomarkers of TKI resistance. Taken together, whole exome sequencing of cell-based or patients-derived samples are highly beneficial to define specific resistance markers. Additionally, this might be helpful for the development of novel diagnostic tools, e.g., liquid biopsy, and novel therapeutic agents, which could be used to overcome TKI resistance in molecularly distinct leukemia subtypes.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2024.1422565","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:52:18Z","timestamp":1721609538000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Molecular biomarkers of leukemia: convergence-based drug resistance mechanisms in chronic myeloid leukemia and myeloproliferative neoplasms"],"prefix":"10.3389","volume":"15","author":[{"given":"Meike","family":"Kaehler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolas","family":"von Bubnoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingolf","family":"Cascorbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivahari Prasad","family":"Gorantla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.3390\/cancers13194820","article-title":"Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia-from molecular mechanisms to clinical relevance","volume":"13","author":"Alves","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"7091","DOI":"10.1038\/ncomms8091","article-title":"Dissecting the role of aberrant DNA methylation in human leukaemia","volume":"6","author":"Amabile","year":"2015","journal-title":"Nat. Commun."},{"key":"B3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1146\/annurev-pharmtox-010617-052954","article-title":"Epigenetic mechanisms regulating adaptive responses to targeted kinase inhibitors in cancer","volume":"58","author":"Angus","year":"2018","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1182\/blood-2014-01-547760","article-title":"Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms","volume":"123","author":"Bhagwat","year":"2014","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e424","DOI":"10.1097\/HS9.0000000000000424","article-title":"JAK inhibition for the treatment of myelofibrosis: limitations and future perspectives","volume":"4","author":"Bose","year":"2020","journal-title":"Hemasphere"},{"key":"B8","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and resistance to BCR-ABL1-targeted therapies","volume":"37","author":"Braun","year":"2020","journal-title":"Cancer Cell"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1038\/s41375-021-01391-2","article-title":"Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy","volume":"35","author":"Brkic","year":"2021","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ejca.2017.02.028","article-title":"Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: a systematic review and a meta-analysis","volume":"77","author":"Campiotti","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/14656566.2024.2331778","article-title":"Pharmacotherapeutic advances for chronic myelogenous leukemia: beyond tyrosine kinase inhibitors","volume":"25","author":"Costa","year":"2024","journal-title":"Expert Opin. Pharmacother."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1038\/s41375-023-02048-y","article-title":"European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia","volume":"37","author":"Cross","year":"2023","journal-title":"Leukemia"},{"key":"B13","doi-asserted-by":"publisher","first-page":"86","DOI":"10.33590\/emjoncol\/10311536","article-title":"The importance of mutational analysis in chronic myeloid leukaemia for treatment choice","volume":"4","author":"De Lavallade","year":"2016","journal-title":"Eur. Med. J. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s12032-014-0851-5","article-title":"Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia","volume":"31","author":"De Lima","year":"2014","journal-title":"Med. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/leu.2011.255","article-title":"Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms","volume":"26","author":"Deshpande","year":"2012","journal-title":"Leukemia"},{"key":"B16","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"114643","DOI":"10.1016\/j.biopha.2023.114643","article-title":"Overcoming cancer multi-drug resistance (MDR): reasons, mechanisms, nanotherapeutic solutions, and challenges","volume":"162","author":"Duan","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"B18","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/clpt.2013.208","article-title":"Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib","volume":"95","author":"Eadie","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ccell.2019.08.004","article-title":"Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants","volume":"36","author":"Eide","year":"2019","journal-title":"Cancer Cell"},{"key":"B20","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1186\/s13059-014-0461-8","article-title":"Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia","volume":"15","author":"Eiring","year":"2014","journal-title":"Genome Biol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1158\/2159-8290.CD-15-1434","article-title":"Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation","volume":"6","author":"Elf","year":"2016","journal-title":"Cancer Discov."},{"key":"B22","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-term follow-up of the French stop imatinib (STIM1) study in patients with chronic myeloid leukemia","volume":"35","author":"Etienne","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1038\/s41375-019-0379-y","article-title":"Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NF\u03baB signaling","volume":"33","author":"Fisher","year":"2019","journal-title":"Leukemia"},{"key":"B24","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1158\/1535-7163.MCT-12-0862","article-title":"Dual PI3K\/AKT\/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells","volume":"12","author":"Fiskus","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/1878-0261.13566","article-title":"A newly identified 45-kDa JAK2 variant with an altered kinase domain structure represents a novel mode of JAK2 kinase inhibitor resistance","volume":"18","author":"Gorantla","year":"2024","journal-title":"Mol. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.5045\/br.2023.2023035","article-title":"Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia","volume":"58","author":"Han","year":"2023","journal-title":"Blood Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1182\/blood-2010-07-294330","article-title":"Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib","volume":"117","author":"Haouala","year":"2011","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/306239a0","article-title":"Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia","volume":"306","author":"Heisterkamp","year":"1983","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.canlet.2014.10.006","article-title":"MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein","volume":"356","author":"Hershkovitz-Rokah","year":"2014","journal-title":"Cancer Lett."},{"key":"B30","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"B31","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2174\/1568009615666150921141004","article-title":"New insights into the molecular resistance mechanisms of chronic myeloid leukemia","volume":"16","author":"Huang","year":"2016","journal-title":"Curr. Cancer Drug Targets"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1200\/JCO.2012.42.1925","article-title":"Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study","volume":"30","author":"Hultcrantz","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.3390\/cancers12092381","article-title":"Murine models of myelofibrosis","volume":"12","author":"Jacquelin","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41586-020-2968-3","article-title":"Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms","volume":"588","author":"Jayavelu","year":"2020","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/164_2023_639","article-title":"Molecular mechanisms of tyrosine kinase inhibitor resistance in chronic myeloid leukemia","volume":"280","author":"Kaehler","year":"2023","journal-title":"Handb. Exp. Pharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1200897","DOI":"10.3389\/fonc.2023.1200897","article-title":"Clonal evolution in tyrosine kinase inhibitor-resistance: lessons from in vitro-models","volume":"13","author":"Kaehler","year":"2023","journal-title":"Front. Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"14538","DOI":"10.1038\/srep14538","article-title":"Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance","volume":"5","author":"Kesarwani","year":"2015","journal-title":"Sci. Rep."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"B42","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.leukres.2017.06.009","article-title":"Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy","volume":"59","author":"Kim","year":"2017","journal-title":"Leuk. Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40164-020-00183-1","article-title":"Expression differences of miR-142-5p between treatment-naive chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance","volume":"9","author":"Klumper","year":"2020","journal-title":"Exp. Hematol. Oncol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nature11303","article-title":"Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy","volume":"489","author":"Koppikar","year":"2012","journal-title":"Nature"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1038\/ng1799","article-title":"Strategies to determine the biological function of microRNAs","volume":"38","author":"Krutzfeldt","year":"2006","journal-title":"Nat. Genet."},{"key":"B48","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat. Genet."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s11010-022-04376-6","article-title":"Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review","volume":"477","author":"Kumar","year":"2022","journal-title":"Mol. Cell Biochem."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.3390\/cancers12082278","article-title":"Finding a jill for JAK: assessing past, present, and future JAK inhibitor combination approaches in myelofibrosis","volume":"12","author":"Kuykendall","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B51","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13045-018-0585-5","article-title":"Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis","volume":"11","author":"Kvasnicka","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41467-020-20259-0","article-title":"Targeting USP47 overcomes tyrosine kinase inhibitor resistance and eradicates leukemia stem\/progenitor cells in chronic myelogenous leukemia","volume":"12","author":"Lei","year":"2021","journal-title":"Nat. Commun."},{"key":"B53","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"B54","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.bbrc.2012.07.098","article-title":"Myc induced miR-144\/451 contributes to the acquired imatinib resistance in chronic myelogenous leukemia cell K562","volume":"425","author":"Liu","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B55","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.leukres.2012.12.003","article-title":"Decreased microRNA-30a levels are associated with enhanced ABL1 and BCR-ABL1 expression in chronic myeloid leukemia","volume":"37","author":"Liu","year":"2013","journal-title":"Leuk. Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ejh.13408","article-title":"The multi-tyrosine kinase inhibitor ponatinib for chronic myeloid leukemia: real-world data","volume":"105","author":"Luciano","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41375-023-02109-2","article-title":"The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib","volume":"38","author":"Machova Polakova","year":"2024","journal-title":"Leukemia"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1182\/blood-2013-05-504555","article-title":"Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors","volume":"123","author":"Marty","year":"2014","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","article-title":"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML","volume":"368","author":"Maxson","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1182\/bloodadvances.2019000260","article-title":"The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN","volume":"3","author":"Mazzacurati","year":"2019","journal-title":"Blood Adv."},{"key":"B61","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/leu.2008.27","article-title":"Targeting survival cascades induced by activation of Ras\/Raf\/MEK\/ERK, PI3K\/PTEN\/Akt\/mTOR and Jak\/STAT pathways for effective leukemia therapy","volume":"22","author":"Mccubrey","year":"2008","journal-title":"Leukemia"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1016\/j.drudis.2019.05.007","article-title":"Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options","volume":"24","author":"Meenakshi Sundaram","year":"2019","journal-title":"Drug Discov. Today"},{"key":"B63","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3109\/10428194.2013.813500","article-title":"Epidemiology of myeloproliferative neoplasms in the United States","volume":"55","author":"Mehta","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"B64","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ccell.2015.06.006","article-title":"CHZ868, a type II JAK2 inhibitor, reverses type I JAK inhibitor persistence and demonstrates efficacy in myeloproliferative neoplasms","volume":"28","author":"Meyer","year":"2015","journal-title":"Cancer Cell"},{"key":"B65","doi-asserted-by":"publisher","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-09-1068","article-title":"Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia","volume":"15","author":"Milojkovic","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"B66","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3390\/cells10010117","article-title":"Chronic myeloid leukemia: a model disease of the past, present and future","volume":"10","author":"Minciacchi","year":"2021","journal-title":"Cells"},{"key":"B67","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.biopha.2018.02.038","article-title":"Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR","volume":"100","author":"Mohammad","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"B68","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41467-019-13892-x","article-title":"Single-cell analysis based dissection of clonality in myelofibrosis","volume":"11","author":"Mylonas","year":"2020","journal-title":"Nat. Commun."},{"key":"B69","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1158\/2643-3230.BCD-22-0189","article-title":"Next-generation JAK2 inhibitors for the treatment of myeloproliferative neoplasms: lessons from structure-based drug discovery approaches","volume":"4","author":"Nair","year":"2023","journal-title":"Blood Cancer Discov."},{"key":"B70","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1158\/1078-0432.CCR-13-1999","article-title":"Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1)","volume":"20","author":"Nies","year":"2014","journal-title":"Clin. cancer Res. official J. Am. Assoc. Cancer Res."},{"key":"B72","first-page":"85","article-title":"Chromosome studies on normal and leukemic human leukocytes","volume":"25","author":"Nowell","year":"1960","journal-title":"J. Natl. Cancer Inst."},{"key":"B73","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'hare","year":"2009","journal-title":"Cancer Cell"},{"key":"B74","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrc3317","article-title":"Pushing the limits of targeted therapy in chronic myeloid leukaemia","volume":"12","author":"O'hare","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"B75","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41408-022-00609-5","article-title":"JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation","volume":"12","author":"Pandey","year":"2022","journal-title":"Blood Cancer J."},{"key":"B76","doi-asserted-by":"publisher","first-page":"e335","DOI":"10.1038\/bcj.2015.63","article-title":"A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis","volume":"5","author":"Pardanani","year":"2015","journal-title":"Blood Cancer J."},{"key":"B77","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2020-136938","article-title":"The addition of navitoclax to ruxolitinib demonstrates efficacy within different high-risk populations in patients with relapsed\/refractory myelofibrosis","volume":"136","author":"Pemmaraju","year":"2020","journal-title":"Blood"},{"key":"B78","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","article-title":"Clinical pharmacokinetics of imatinib","volume":"44","author":"Peng","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"B79","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med."},{"key":"B80","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/s0889-8588(05)70198-2","article-title":"Philadelphia chromosome-positive acute lymphocytic leukemia","volume":"15","author":"Radich","year":"2001","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"B81","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1177\/1947601912462126","article-title":"The ins and outs of bcr-abl inhibition","volume":"3","author":"Reddy","year":"2012","journal-title":"Genes and cancer"},{"key":"B82","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"","journal-title":"Blood"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"","journal-title":"Blood"},{"key":"B85","doi-asserted-by":"publisher","first-page":"8931","DOI":"10.1002\/cam4.3516","article-title":"The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort","volume":"9","author":"Sato","year":"2020","journal-title":"Cancer Med."},{"key":"B86","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1046\/j.1365-2141.1997.d01-1982.x","article-title":"Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period","volume":"96","author":"Savage","year":"1997","journal-title":"Br. J. Haematol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"B88","doi-asserted-by":"publisher","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","article-title":"Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1","volume":"61","author":"Schoepfer","year":"2018","journal-title":"J. Med. Chem."},{"key":"B89","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"B90","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/bjh.18883","article-title":"Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: final 5-year analysis of DASFREE","volume":"202","author":"Shah","year":"2023","journal-title":"Br. J. Haematol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1172\/JCI30890","article-title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency","volume":"117","author":"Shah","year":"2007","journal-title":"J. Clin. Investig."},{"key":"B92","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1159\/000512929","article-title":"Accelerated phase of myeloproliferative neoplasms","volume":"144","author":"Shahin","year":"2021","journal-title":"Acta Haematol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.leukres.2013.07.019","article-title":"Imatinib induces demethylation of miR-203 gene: an epigenetic mechanism of anti-tumor effect of imatinib","volume":"37","author":"Shibuta","year":"2013","journal-title":"Leuk. Res."},{"key":"B94","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"Ca-a Cancer J. Clin."},{"key":"B95","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/2040620712461047","article-title":"Comprehensive review of JAK inhibitors in myeloproliferative neoplasms","volume":"4","author":"Sonbol","year":"2013","journal-title":"Ther. Adv. Hematol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1002\/cncr.28522","article-title":"Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: the main changes are in the type of mutations, but not in the frequency of mutation involvement","volume":"120","author":"Soverini","year":"2014","journal-title":"Cancer"},{"key":"B97","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.3324\/haematol.2018.193086","article-title":"BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia","volume":"103","author":"Srutova","year":"2018","journal-title":"Haematologica"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1172\/JCI98785","article-title":"Targeting compensatory MEK\/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms","volume":"129","author":"Stivala","year":"2019","journal-title":"J. Clin. Investig."},{"key":"B99","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2174\/1389200221666200620210522","article-title":"2020 fda drug-drug interaction guidance: a comparison analysis and action plan by pharmaceutical industrial scientists","volume":"21","author":"Sudsakorn","year":"2020","journal-title":"Curr. Drug Metab."},{"key":"B100","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.mayocp.2018.08.022","article-title":"3023 mayo clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups","volume":"94","author":"Szuber","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1200\/GO.21.00058","article-title":"Spectrum of BCR-ABL mutations and treatment outcomes in Ethiopian imatinib-resistant patients with chronic myeloid leukemia","volume":"7","author":"Tadesse","year":"2021","journal-title":"JCO Glob. Oncol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"key":"B103","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1001\/jamaoncol.2015.89","article-title":"Myeloproliferative neoplasms: a contemporary review","volume":"1","author":"Tefferi","year":"2015","journal-title":"JAMA Oncol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"eaat3834","DOI":"10.1126\/sciadv.aat3834","article-title":"Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis","volume":"4","author":"Tvorogov","year":"2018","journal-title":"Sci. Adv."},{"key":"B105","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13045-017-0527-7","article-title":"Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses","volume":"10","author":"Verstovsek","year":"","journal-title":"J. Hematol. Oncol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B107","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","article-title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","volume":"10","author":"Verstovsek","year":"","journal-title":"J. Hematol. Oncol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0140-6736(02)07679-1","article-title":"BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study","volume":"359","author":"Von Bubnoff","year":"2002","journal-title":"Lancet"},{"key":"B109","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/clpt.2014.129","article-title":"Functional gene variants of CYP3A4","volume":"96","author":"Werk","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"B110","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.1182\/blood-2006-11-058032","article-title":"Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs","volume":"109","author":"White","year":"2007","journal-title":"Blood"},{"key":"B111","doi-asserted-by":"publisher","first-page":"ra122","DOI":"10.1126\/scisignal.2005301","article-title":"RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis","volume":"7","author":"Winter","year":"2014","journal-title":"Sci. Signal"},{"key":"B112","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1422565\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:52:22Z","timestamp":1721609542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1422565\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":112,"alternative-id":["10.3389\/fphar.2024.1422565"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1422565","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,22]]},"article-number":"1422565"}}